Antithrombotic Drugs Market 2017-2027

1. Report Overview

1.1 Overview of the World Market for Antithrombotic Drugs

1.2 Why Should You Read This Report

1.3 How This Report Delivers

1.4 Main Questions Answered by This Analysis

1.5 Who Is This Study For?

1.6 Methods of Research and Analysis

1.7 Frequently Asked Questions (FAQs)

1.8 Some Associated Reports

1.9 About Visiongain

1.10 Glossary of Abbreviations

2. Blood Clotting: Mechanisms, Disorders and Current Treatments

2.1 Understanding Haemostasis and Coagulation

2.2 What is Thrombosis

2.3 Complications of Thrombosis

2.3.1 Pulmonary Embolism: A Thrombus Blocking Blood Supply to the Lungs

2.3.2 Stroke Results From Blockage of Blood Flow to the Brain

2.3.3 Acute Coronary Syndrome (ACS): Blockage of Blood Supply to the Heart

2.4 Antithrombotic Drug Treatment

3. Antithrombotic Drugs: World Market 2017-2027

3.1 The World Antithrombotic Drug Market in 2015 and 2016

3.2 The World Antithrombotic Drug Market: Overarching Revenue Forecast 2016-2027

3.3 Driving and Restraining Forces Affecting the Antithrombotic Drugs Market

3.3.1 An Increasing Patient Population Drives Market Growth

3.3.2 Intense Competition from Generics Threatens to Restrain the Market

3.4 The Antithrombotic Drug Market by Therapeutic Class: Revenue and Market Share Predictions, 2019 and 2025

3.5 The Future of the World Market for Antithrombotic Drugs by Therapeutic Class: Grouped Revenue Forecasts, 2016-2027

3.6 Anticoagulant Drugs: Leading the Market from 2016 Onwards

3.6.1 Direct Factor Xa Inhibitors: A Novel Therapeutic Class with Great Potential

3.6.2 Heparins: The Second-Leading Anticoagulant Class in 2016

3.6.3 Direct Thrombin Inhibitors Achieved High Growth in 2015 and 2016

3.6.4 Vitamin K Antagonists Have Led the Anticoagulant Drug Market for 60 Years

3.7 Antiplatelet Drugs Were the Second-Leading Therapeutic Class in 2016

3.8 Fibrinolytics Will Continue to be a Staple of the Antithrombotic Drug Market

4. Leading Products in the Market: Prospects, 2017-2027

4.1 Xarelto and Eliquis Remain the Market Leaders in 2016, Despite Generic Competition

4.2 The Leading Antithrombotic Drugs: Comparison of Revenue and Market Share, 2022 and 2027

4.3 Which Medicines Will Achieve the Highest Rate of Growth to 2027?

4.4 Plavix Faces Competition from Generics, So What Does the Future Hold?

4.4.1 Branded Competition for Plavix?

4.5 Lovenox: Biosimilar Competition in the EU is Expected

4.6 Xarelto: Leading Antithrombotic of 2015

4.7 Pradaxa’s Continued Growth in 2016

4.8 Activase Leads the Fibrinolytics Market, With Little Competition

4.9 Effient Competes with Brilinta/Brilique as well as Generic Competition for Plavix

4.10 Aspirin Cardio: The Most Lucrative Version of Acetylsalicylic Acid

4.11 Angiomax/Angiox is Losing Share of the Direct Thrombin Inhibitors Market to Pradaxa

4.12 Pletal Faces Generic Competition and Restrictions on Use in Europe

4.13 Aggrenox/Asasantin to Face Generic Competition Earlier Than Expected in the US

4.14 Fragmin Faces Rivalry from Generic Competition to Lovenox

4.15 Brilinta/Brilique: Investigation Closed in 2014

4.16 Eliquis: Will Late Entry to the Market Affect Uptake?

4.17 Arixtra: Aspen Pharmacare Has Acquired Worldwide Rights from GSK

4.18 New Approvals in the Antithrombotic Drugs Market

4.18.1 Zontivity: The Newest Approval In Antithrombotics

4.18.2 Lixiana/Savaysa: Expansion into Other Regional Markets

5. Leading National Markets 2016-2027

5.1 Which Were the Leading National Markets for Sales of Antithrombotic Drugs in 2015 and 2016?

5.2 The Leading National Markets for Antithrombotic Drugs: Comparison of Revenues and Market Shares, 2021 and 2027

5.3 Which National Markets Will Grow Fastest to 2027?

5.4 The US: Dominating the Antithrombotic Drug Market Through 2016-2027

5.5 The EU5: Are the Guidelines for Approval of Biosimilar LMWHs Set to Change?

5.5.1 Germany Leads the EU5

5.5.2 France: Healthcare System Reform Will Inhibit Sales Growth?

5.5.3 UK: Pharmaceutical Price Regulation Scheme

5.5.4 Italy’s Healthcare System - Advantages Conducive to Business

5.5.5 Spain: Reductions in Governmental Healthcare Spending Will Restrict Growth

5.6 Japan: The Aging Population Will Stimulate Demand for Antithrombotic Drugs from 2017-2027

5.7 The Chinese Antithrombotic Drug Market Will Capture Market Share

5.8 The Brazilian Antithrombotic Drug Market 2017-2027: Strong Growth as Universal Healthcare Coverage is Expanded

5.9 The Indian Antithrombotic Drug Market - Limited by Governmental Healthcare Spending?

5.10 The Russian Antithrombotic Drug Market: Limited Healthcare Funding Will Prevent Expansive Growth

6. Antithrombotic Drug Development: R&D Pipeline

6.1 The R&D Pipeline for Antithrombotic Drugs: Overview

6.2 The Antiplatelet Drug R&D Pipeline in 2016

6.2.1 Pozen is Seeking a Strategic Partner for its Antiplatelet Drug, PA32540

6.2.2 The Medicines Company’s Kangrexel (Cangrelor) Received Approval

6.3 The R&D Pipeline for Anticoagulants, 2016

6.3.1 Heparins: Little R&D Activity in 2016

6.3.2 The Vitamin K Antagonist Pipeline

6.3.3 Many Development Direct Thrombin Inhibitors Have Been Discontinued

6.3.4 The Direct Factor Xa Inhibitor Pipeline: Only Two Compounds Remain

6.3.5 Portola Pharmaceuticals’ Betrixaban

6.3.6 Sanofi Has Apparently Discontinued Development of Otamixaban

6.4 The Fibrinolytics R&D Pipeline, 2016

6.4.1 Lundbeck’s Desmoteplase: Failed to Meet Primary Endpoint in Phase III

6.4.2 Bharat Biotech and ThromboGenics’ THR-100

6.5 The R&D Pipeline for Other Antithrombotic Drugs, 2016

6.5.1 Kyowa Hakko Kirin’s KW-3357: Filed in Japan

6.5.2 Asahi Kasei Pharma America’s ART 123

6.5.3 Regado Biosciences/Tobira Therapeutics is Developing an Anticoagulation System with an Antidote

6.5.4 Isis Pharmaceuticals’ ISIS-FXI Rx

7. Leading Companies in the Antithrombotic Drug Market

7.1 Leading Antithrombotic Drug Manufacturers in 2015 and 2016

7.2 Sanofi Leads the Market, but is its Position Under Threat?

7.3 Boehringer Ingelheim Captures Market Share

7.4 Bayer Markets Two Antithrombotic Drugs

7.5 Johnson & Johnson Can Achieve Success with a Limited Product Portfolio

7.6 Genentech Will Retain Market Share

7.7 The Medicines Company’s Position Will be Bolstered by the Launch of its New Drug

7.8 Eli Lilly: Market Position is Dependent on Success of Effient

7.9 Otsuka: A Limited Antithrombotic Drug Portfolio

7.10 Pfizer: A Gradually Increasing Share of the Market

7.11 Bristol-Myers Squibb Expected to Lead the Market 2017 onwards

8. Qualitative Analysis of the Antithrombotic Drugs Market, 2016

8.1 The Strengths and Weaknesses of the Antithrombotic Drug Market in 2016

8.1.1 Thrombotic Disease: Management Rather Than Cure

8.1.2 The Lack of Antidotes for the Novel Oral Anticoagulants Restricts the Market

8.2 Opportunities and Threats Facing the Market 2016-2027

8.2.1 Rising Disease Prevalence Creates Opportunities in the Market

8.2.2 Further Development of Existing Drugs

8.2.3 High Demand for Antidotes to the Novel Oral Anticoagulants

8.2.4 The Threat of Generic Competition

8.2.5 High Level of Competition is a Threat to New Entrants - What Can Developers Do?

8.2.6 High Risk of Investment in New Drug Development

8.2.7 Healthcare Budget Pressures Threaten Drug Launches and Prices in Europe

8.3 Social, Technological, Economic and Political Factors Influencing the Antithrombotic Drug Market 2017-2027

8.3.1 Social Factors: An Expanding Patient Population and Increasing Awareness

8.3.2 Technological Advances Encourage the Development of Improved Treatment Options

8.3.3 Economic Factors

8.3.4 Political Factors: Will the Affordable Care Act Increase Patient Access to Antithrombotic Drugs?

9. Conclusions from Our Study

9.1 The World Market for Antithrombotic Drugs 2017-2027

9.1.1 The Decline of Antiplatelet Drugs and the Rise of the Anticoagulants

9.2 The Leading National Markets 2017-2027

9.3 Trends in the Industry

9.3.1 The Market Will Recover From Plavix Decline

9.3.2 The Demand for Antithrombotic Drugs is Increasing Worldwide

9.3.3 Many Drugs Will Face Generic Competition Over the Coming 10 Years

9.3.4 High Barriers to Market Entry and a Limited Pipeline – The Implications

Appendices

Some Associated Reports

Visiongain Report Sales Order Form

About Visiongain

Report Evaluation Form

List of Tables

Table 1.3 Foreign Currency Exchange Rates: Average Exchange Rate to USD, 2015 and 2016

Table 2.1 An Overview of Antithrombotic Drugs by Therapeutic Class, 2014

Table 3.1 The Antithrombotic Drug Market by Therapeutic Class: Revenues ($m) and Market Shares (%), 2015 and 2016

Table 3.2 Overall World Market for Antithrombotic Drugs: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 3.3 The Antithrombotic Drug Market by Therapeutic

Class: Comparison of Revenues ($m) and Market Shares (%), 2021 and 2027

Table 3.4 The Antithrombotic Drug Market by Therapeutic Class: Revenue ($m), AGR (%) and CAGR (%) Forecasts, 2016-2027

Table 3.5 Anticoagulant Drugs: Grouped Revenue Forecasts ($m) by Subclass, 2016-2027

Table 3.6 Direct Factor Xa Inhibitors: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 3.7 Heparins: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 3.8 Direct Thrombin Inhibitors: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 3.9 The Warfarin Market: Companies and Year of Introduction

Table 3.10 Vitamin K Antagonists: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 3.11 Antiplatelet Drugs: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 3.12 Fibrinolytics: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 4.1 Leading Antithrombotic Drugs: Revenues ($m) and Market Shares (%), 2015 and 2016

Table 4.2 Leading Antithrombotic Drugs: Comparison of Revenues ($m) and Market Shares (%), 2019 and 2025

Table 4.3 Leading Antithrombotic Drugs: Revenue Forecasts ($m), 2016-2027

Table 4.4 Plavix: Key Facts, 2016

Table 4.5 Selected Generic Competitors Approved by the FDA, 2016

Table 4.6 Plavix: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 4.7 Lovenox: Key Facts, 2016

Table 4.8 Lovenox: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 4.9 Xarelto: Key Facts, 2016

Table 4.10 Xarelto: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 4.11 Pradaxa: Key Facts, 2014

Table 4.12 Pradaxa: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 4.13 Activase: Key Facts, 2016

Table 4.14 Activase: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 4.15 Effient: Key Facts, 2016

Table 4.16 Effient: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 4.17 Aspirin Cardio: Key Facts, 2016

Table 4.18 Aspirin Cardio: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 4.19 Angiomax/Angiox: Key Facts, 2016

Table 4.20 Angiomax/Angiox: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 4.21 Pletal: Key Facts, 2016

Table 4.22 Pletal: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 4.23 Aggrenox/Asasantin: Key Facts, 2016

Table 4.24 Aggrenox/Asasantin: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 4.25 Fragmin: Key Facts, 2016

Table 4.26 Fragmin: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 4.27 Brilinta: Key Facts, 2016

Table 4.28 Brilinta: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 4.29 Eliquis: Key Facts, 2016

Table 4.30 Eliquis: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 4.31 Arixtra: Key Facts, 2016

Table 4.32 Zontivity: Key Facts, 2016

Table 4.33 Lixiana/Savaysa: Key Facts, 2016

Table 5.1 The Leading National Markets for Antithrombotic Drugs: Revenues ($m) and Market Shares (%), 2015 and 2016

Table 5.2 The Leading National Markets for Antithrombotic Drugs: Comparison of Revenues ($m) and Market Shares (%), 2021 and 2027

Table 5.3 The Leading National Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2016-2027

Table 5.4 The US Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 5.5 The EU5 Market for Antithrombotic Drugs: National Revenue ($m), AGR (%) and CAGR (%) Forecasts, 2016-2027

Table 5.6 The German Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 5.7 The French Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 5.8 The UK Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 5.9 The Italian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 5.10 The Spanish Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 5.11 The Japanese Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 5.12 The Chinese Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 5.13 The Brazilian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 5.14 The Indian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 5.15 The Russian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027

Table 6.1 Selected Candidates in the Antiplatelet Drug R&D Pipeline, 2016

Table 6.2 Selected Candidates in the Heparins Pipeline, 2016

Table 6.3 Selected Candidates in the Vitamin K Antagonist Pipeline, 2014

Table 6.4 Candidates in the Direct Thrombin Inhibitors Pipeline, 2016

Table 6.5 The Direct Factor Xa Inhibitor Pipeline, 2016

Table 6.6 The Fibrinolytics R&D Pipeline, 2016

Table 6.7 Other Antithrombotic Drugs in Development, 2016

Table 7.1 The Top 10 Companies: Revenues ($m) and Market Shares (%), 2015 and 2016

Table 7.2 Sanofi: Antithrombotic Drug Portfolio, 2016

Table 7.3 Boehringer Ingelheim: Antithrombotic Drug Portfolio, 2016

Table 7.4 Bayer: Antithrombotic Drug Portfolio, 2016

Table 7.5 Johnson & Johnson: Antithrombotic Drug Portfolio, 2016

Table 7.6 Genentech: Antithrombotic Drug Portfolio, 2016

Table 7.7 The Medicines Company: Antithrombotic Drug Portfolio, 2016

Table 7.8 Eli Lilly: Antithrombotic Drug Portfolio, 2016

Table 7.9 Otsuka: Antithrombotic Drug Portfolio, 2016

Table 7.10 Pfizer: Antithrombotic Drug Portfolio, 2016

Table 7.11 Bristol-Myers Squibb: Antithrombotic Drug Portfolio, 2016

Table 8.1 Strengths and Weaknesses of the Antithrombotic Drug Market, 2016

Table 8.2 Opportunities and Threats Facing the Antithrombotic Drug Market, 2016-2027

Table 8.3 Social, Technological, Economic and Political Forces Influencing the Antithrombotic Drug Market (STEP Analysis), 2017-2027

List of Figures

Figure 2.1 Diagram Depicting the Coagulation Cascade

Figure 3.1 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2015

Figure 3.2 The Antithrombotic Drug Market by Therapeutic

Class: Market Share (%), 2016

Figure 3.3 The Global Market for Antithrombotic Drugs: Revenue Forecast ($m), 2016-2027

Figure 3.4 The Antithrombotic Drug Market: Drivers and Restraints, 2017-2027

Figure 3.5 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2021

Figure 3.6 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2027

Figure 3.7 The Antithrombotic Drug Market by Therapeutic Class: Revenue Forecasts ($m), 2016-2027

Figure 3.8 Anticoagulant Drugs: Grouped Revenue Forecasts ($m) by Subclass, 2016-2027

Figure 3.9 Direct Factor Xa Inhibitors: Revenue Forecast ($m), 2016-2027

Figure 3.10 Direct Factor Xa Inhibitors Market: Drivers and Restraints, 2017-2027

Figure 3.11 Heparins: Revenue Forecast ($m), 2016-2027

Figure 3.12 The Heparins Market: Drivers and Restraints, 2017-2027

Figure 3.13 Direct Thrombin Inhibitors: Revenue Forecast ($m), 2016-2027

Figure 3.14 The Direct Thrombin Inhibitors Market: Drivers and Restraints, 2017-2027

Figure 3.15 Vitamin K Antagonists: Revenue Forecast ($m), 2016-2027

Figure 3.16 The Vitamin K Antagonist Market: Drivers and Restraints, 2016-2027

Figure 3.17 Antiplatelet Drugs: Revenue Forecast ($m), 2016-2027

Figure 3.18 The Antiplatelet Drug Market: Drivers and Restraints, 2017-2027

Figure 3.19 Fibrinolytics: Revenue Forecast ($m), 2016-2027

Figure 3.20 The Fibrinolytics Market: Drivers and Restraints, 2017-2027

Figure 4.1 The Leading Antithrombotic Drugs: Market Shares (%), 2015

Figure 4.2 The Leading Antithrombotic Drugs: Market Shares (%), 2016

Figure 4.3 The Leading Antithrombotic Drugs: Market Shares (%), 2022

Figure 4.4 The Leading Antithrombotic Drugs: Market Shares (%), 2027

Figure 4.5 Leading Antithrombotic Drugs: Revenue Forecasts ($m), 2016-2027

Figure 4.6 Plavix: Revenue Forecast ($m), 2016-2027

Figure 4.7 Lovenox: Revenue Forecast ($m), 2016-2027

Figure 4.8 Xarelto: Revenue Forecast ($m), 2016-2027

Figure 4.9 Pradaxa: Revenue Forecast ($m), 2016-2027

Figure 4.10 Activase: Revenue Forecast ($m), 2016-2027

Figure 4.11 Effient: Revenue Forecast ($m), 2016-2027

Figure 4.12 Aspirin Cardio: Revenue Forecast ($m), 2016-2027

Figure 4.13 Angiomax/Angiox: Revenue Forecast ($m), 2016-2027

Figure 4.14 Pletal: Revenue Forecast ($m), 2016-2027

Figure 4.15 Aggrenox/Asasantin: Revenue Forecast ($m), 2016-2027

Figure 4.16 Fragmin: Revenue Forecast ($m), 2016-2027

Figure 4.17 Brilinta: Revenue Forecast ($m), 2016-2027

Figure 4.18 Eliquis: Revenue Forecast ($m), 2014-2025

Figure 5.1 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2015

Figure 5.2 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2016

Figure 5.3 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2021

Figure 5.4 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2027

Figure 5.5 Leading National Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2016-2027

Figure 5.6 The US Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027

Figure 5.7 The US Antithrombotic Drug Market: Drivers and Restraints, 2016-2027

Figure 5.8 EU5 Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2016-2027

Figure 5.9 EU5 Antithrombotic Drug Market: Drivers and Restraints, 2016-2027

Figure 5.10 The German Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027

Figure 5.11 The French Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027

Figure 5.12 The UK Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025

Figure 5.13 The Italian Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027

Figure 5.14 The Spanish Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027

Figure 5.15 The Japanese Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027

Figure 5.16 The Japanese Antithrombotic Drug Market: Drivers and Restraints, 2017-2027

Figure 5.17 The Chinese Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027

Figure 5.18 The Chinese Antithrombotic Drug Market: Drivers and Restraints, 2017-2027

Figure 5.19 The Brazilian Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027

Figure 5.20 The Brazilian Antithrombotic Drug Market: Drivers and Restraints, 2017-2027

Figure 5.21 The Indian Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027

Figure 5.22 The Indian Antithrombotic Drug Market: Drivers and Restraints, 2017-2027

Figure 5.23 The Russian Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027

Figure 5.24 The Russian Antithrombotic Drug Market: Drivers and Restraints, 2017-2027

Figure 6.1 An Overview of the R&D Pipeline for Antithrombotic Drugs, 2016

Figure 7.1 The Top 10 Companies: Market Shares (%), 2015

Figure 7.2 The Top 10 Companies: Market Shares (%), 2016

Figure 9.1 The Global Antithrombotic Drug Market by Therapeutic Class: Comparison of Revenues ($m), 2015-2027

Figure 9.2 Leading National Markets for Antithrombotic Drugs: Comparison of Revenues ($m), 2016, 2021 and 2027